Browse
Log in / Register
Share
March 20, 2026 — Higher progesterone may make it harder for the brain to tell simple emotional situations from complex ones, according to a new study from the University of Barcelona. The brain pattern tied to higher hormone levels tracked with lower mood, offering a biological route for the monthly mood shifts that many women say they experience. The work appears in Psychological Medicine.
Progesterone surges after ovulation and stays high through the luteal phase—the stretch between ovulation and the start of the next period. That makes it a natural suspect in premenstrual mood changes, but proving its role has been tricky. Several hormones rise and fall together in a monthly rhythm. Animal studies point one way, human self-reports another. The Barcelona team built the study to close some of that gap by combining hormone measurements with a brain-reading method that looks at neural patterns, not just activation levels.
The study included 116 young, healthy women with natural menstrual cycles. None of them was using hormonal contraceptives, a deliberate design decision. Birth control pills do more than prevent pregnancy: they suppress the body's own hormone production and substitute synthetic hormones, which would have muddied the results. Saliva samples captured progesterone and other hormone levels around the time of the brain scan.
For the scan, participants viewed emotional facial expressions that varied in complexity. The critical analysis used multivoxel decoding, which examines how patterns of activity across many brain voxels—small three-dimensional units of brain tissue—differ between conditions. Rather than asking whether a given region became more or less active, this approach asks whether the brain's pattern of activity is distinct enough to tell one type of emotional situation from another.
That distinction turned out to matter. Women with higher progesterone showed less separation between simple and complex emotional conditions. The neural code appeared to blur as progesterone rose. And that blur was linked to lower mood scores.
The ability to read emotion quickly and correctly is not a luxury; it underpins daily social life. Distinguishing a genuinely annoyed expression from a neutral one, or a teasing remark from a hostile one, shapes how people respond in conversations, at work, and in close relationships. When that discrimination becomes less reliable, the cost is often social friction and inner distress.
The study's authors did not measure behavior directly, but the neural blur they observed is the kind of change that would plausibly surface as irritability, tearfulness, or a sense of being "off." That makes the finding more than an interesting scan result. It connects a measurable biological state to a very human experience.
The result dovetails with everyday experience. In the luteal phase, small social frictions sometimes feel unbearable; a comment that would normally slide off can sting. If high progesterone reduces the brain's ability to discriminate emotional details, the world may genuinely feel more ambiguous—and more exhausting to navigate. Simple faces may no longer look clearly friendly, angry, or neutral.
The study was published in a well-regarded psychiatry journal, which adds weight to the finding and reflects growing acceptance of hormonal brain research in mainstream psychiatry.
Around 5–8% of women meet criteria for premenstrual dysphoric disorder (PMDD), a severe mood condition recognized in DSM-5. Unlike general PMS, PMDD can include marked depression, anxiety, and irritability that interfere with functioning. SSRIs are a common first-line treatment, and hormonal contraceptives can help by suppressing ovulation, but response is variable. Many women end up cycling through options before finding something that works.
A brain marker like the one described here could eventually help doctors match treatments to individual women. If a woman's brain decoding profile shows a strong progesterone-linked blur, she might benefit from cycle-timed cognitive behavioral therapy, a different antidepressant schedule, or a clearer conversation about ovulation suppression. That level of precision does not exist in routine care today.
The new study extends a growing literature on hormones and emotional brain function. Previous work has implicated progesterone and its neuroactive metabolites in the modulation of the amygdala, a structure central to emotional face processing. Other studies have shown that estrogen fluctuations influence emotional memory and threat sensitivity. But much of this research measured overall brain activity. The Barcelona study is unusual in applying pattern-based decoding to naturally cycling women, asking not just how much the brain reacts, but how clearly it represents different emotions.
That shift mirrors a broader movement in affective neuroscience: the brain is not a set of independent switches, but a dynamic web of distributed patterns. Hormones may reshape those patterns in ways that older experimental methods could not have captured.
The study is not without limitations. The sample was intentionally homogenous—young, healthy, naturally cycling women—which means the findings may not extend to women with clinical depression, postpartum mood disorders, or perimenopause. Hormone levels were measured at a single point, so causation cannot be inferred from the association alone. And although estrogen was presumably accounted for in the analysis, the natural correlation between estrogen and progesterone makes it difficult to completely isolate either hormone's contribution.
Facial emotion tasks also simplify real social perception. Real interactions include tone, gesture, history, and context; a face on a scanner screen lacks all of those. Still, controlled tasks are how affective neuroscience builds mechanistic models, and the pattern-based approach represents an advance over earlier methods.
The most useful next steps involve longitudinal designs. Following women across two or three full cycles, with daily mood diaries and repeated hormone measurements, would show whether the neural blur tracks progesterone in real time. Including women with PMDD would test whether the pattern is exaggerated in clinically significant cases. Trials could then examine whether women with a strong blur respond differently to SSRIs, hormonal contraceptives, or therapy.
There is also a conceptual open question: does progesterone itself affect the brain, or do its neuroactive metabolites—compounds that act on GABA-A receptors and in some ways resemble sedatives—do the work? The distinction matters for drug development. The Barcelona group's methods could help answer it.
For now, the practical message is a mechanism worth attention. Higher progesterone is associated with a less precise emotional code in the brain, and that less precise code is associated with lower mood. If those links hold up in longitudinal studies, an age-old monthly rhythm could become a target for thoughtful, individualized treatment—and a scientific explanation for something women have been describing for generations.
